Dental caries treatment provider vVardis (VVVV.US) submits US IPO application, expected to raise 200 million USD

According to information from Zhihui Finance APP, vVardis Holding (VVVV.US) submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) last Friday. The company specializes in self-developed non-invasive restorative therapies for the treatment of early dental caries. The IPO is expected to raise 200 million USD.

It is understood that the company develops and sells Curodont, a peptide-based early caries treatment that can be completed in five minutes or less at dental clinics without drilling or injections. Its U.S. product, Curodont Repair Fluoride Plus, is sold as an over-the-counter drug under an FDA monograph and contributes the vast majority of revenue. The fluoride-free version, Curodont Repair, is sold as a medical device in the UK and some European regions. In the U.S., sales are exclusively through Henry Schein and are supported by the company's own sales team. The product has been sold to more than 20,000 of the approximately 110,000 general dental practices in the U.S.

This Zug, Switzerland-headquartered company was founded in 2020 and achieved revenues of 50 million USD in the 12 months ended June 30, 2026. The company plans to list on the New York Stock Exchange under the ticker VVVV. vVardis Holding secretly filed its application on July 2, 2026. Goldman Sachs, JPMorgan, William Blair, UBS Investment Bank, Deutsche Bank, and Apollo Global Securities are joint bookrunners for the transaction. Terms related to the pricing of the offering have not yet been disclosed.